| For: | Qiu Q, Duan XW, Li Y, Yang LK, Chen Y, Li H, Duan ZP, Wang L. Impact of partial reimbursement on hepatitis B antiviral utilization and adherence. World J Gastroenterol 2015; 21(32): 9588-9597 [PMID: 26327766 DOI: 10.3748/wjg.v21.i32.9588] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i32/9588.htm |
| Number | Citing Articles |
| 1 |
Feng Zhou, Weidong Jia, Shuo Yang, Ge Chen, Guanhai Li, Yueping Li, Yingfang Liang, Yi Yang, Yanhui Gao, Yue Chen. Antiviral drug Utilization and Annual Expenditures for Patients with Chronic HBV Infection in Guangzhou, China, in 2008–2015. Antiviral Therapy 2019; 24(6) doi: 10.3851/IMP3326
|
| 2 |
Nathan Ford, Roz Scourse, Maud Lemoine, Yvan Hutin, Marc Bulterys, Zara Shubber, Dmytro Donchuk, Gilles Wandeler. Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta‐Analysis. Hepatology Communications 2018; 2(10) doi: 10.1002/hep4.1247
|
| 3 |
Yanxue Lin, Xueping Yu, Huimin Lin, Jiajia Han, Yan Yan, Xiaoting Zhao, Yijie Lin, Zixuan Huang, Yinyin Zheng, Yahong Gao, Wenjin Yuan, Meifang Zhou, Jiming Zhang, Dawu Zeng. Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure. Alimentary Pharmacology & Therapeutics 2025; 62(5) doi: 10.1111/apt.70213
|
| 4 |
Min Li, Lianhui Zhao, Jialing Zhou, Yameng Sun, Xiaoning Wu, Xiaojuan Ou, Hong You, Yuanyuan Kong, Jidong Jia. Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China. The Lancet Regional Health - Western Pacific 2021; 16 doi: 10.1016/j.lanwpc.2021.100249
|
| 5 |
Min Li, Yuan Yuan Kong, Shan Shan Wu, Jia Ling Zhou, Xiao Ning Wu, Lin Wang, Jian Ting Su, Xiao Juan Ou, Hong You, Xue Qin Xie, Zai Hua Wei, Ji Dong Jia. Impact of reimbursement program on liver‐related mortality in patients with chronic hepatitis B in Beijing, China. Journal of Digestive Diseases 2019; 20(9) doi: 10.1111/1751-2980.12794
|
| 6 |
Prowpanga Udompap, Tawesak Tanwandee, Rino Gani. Affordability of Antiviral Therapy in Asia‐Pacific Countries and Its Impact on Public Health Outcomes. Clinical Liver Disease 2020; 16(6) doi: 10.1002/cld.977
|
| 7 |
Keng Lai, Chi Zhang, Weixia Ke, Yanhui Gao, Shudong Zhou, Li Liu, Yi Yang. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China. Clinical Drug Investigation 2017; 37(3) doi: 10.1007/s40261-016-0486-8
|
| 8 |
Hanchao Cheng, Shiyang Liu, Simon Luo, Polin Chan, Zhongdan Chen, Linh‐Vi Le, Jing Sun. Uptake of hepatitis B antiviral treatment: A panel data analysis of 31 provinces in China (2013–2020). Liver International 2022; 42(8) doi: 10.1111/liv.15321
|
| 9 |
玉娇 常. Progress of Research on the Current Status and Influencing Factors of Medication Adherence in Chronic Hepatitis B Patients. Advances in Clinical Medicine 2024; 14(05) doi: 10.12677/acm.2024.1451492
|
| 10 |
Li Xie, Juan Yin, Ruyi Xia, Guihua Zhuang. Cost‐effectiveness of antiviral treatment after resection in hepatitis B virus–related hepatocellular carcinoma patients with compensated cirrhosis. Hepatology 2018; 68(4) doi: 10.1002/hep.29922
|
| 11 |
Rodrigo M Abreu, Leda C Bassit, Sijia Tao, Yong Jiang, Aline S Ferreira, Patrícia CA Hori, Lilia M Ganova-Raeva, Yury Khudyakov, Raymond F Schinazi, Flair J Carrilho, Suzane K Ono. Long-term Virological and Adherence Outcomes to Antiviral Treatment in a 4-year Cohort Chronic HBV Study. Antiviral Therapy 2019; 24(8) doi: 10.3851/IMP3338
|
| 12 |
Xiaodong Guan, Ye Tian, Dennis Ross-Degnan, Chunxia Man, Luwen Shi. Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China. BMJ Open 2018; 8(7) doi: 10.1136/bmjopen-2018-022328
|
| 13 |
Shan Shan, Xinyan Zhao, Jidong Jia. Comprehensive approach to controlling chronic hepatitis B in China. Clinical and Molecular Hepatology 2024; 30(2) doi: 10.3350/cmh.2023.0412
|